Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.96
+0.07003.70%
Post-market: 2.040.0800+4.08%19:44 EDT
Volume:131.00K
Turnover:246.34K
Market Cap:145.71M
PE:-1.69
High:1.97
Open:1.93
Low:1.79
Close:1.89
Loading ...

Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure

THOMSON REUTERS
·
30 Jan

Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability

THOMSON REUTERS
·
30 Jan

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock

Simply Wall St.
·
21 Jan

Inhibikase Adjusts and Terminates Stock Offering Agreement

TIPRANKS
·
06 Dec 2024

Inhibikase Therapeutics Inc - Terminates Atm Agreement With With H.c. Wainwright & Co Llc Effective December 11, 2024

THOMSON REUTERS
·
06 Dec 2024

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders

TIPRANKS
·
19 Nov 2024

Inhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy Rating

TIPRANKS
·
16 Nov 2024

Inhibikase Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Inhibikase Therapeutics Q3 Net Income USD -5.8 Million

THOMSON REUTERS
·
14 Nov 2024

Inhibikase Therapeutics Q3 EPS USD -0.65

THOMSON REUTERS
·
14 Nov 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

THOMSON REUTERS
·
14 Nov 2024

Press Release: Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Dow Jones
·
14 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Nov 2024

Inhibikase Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Jefferies Initiates Inhibikase Therapeutics With Buy Rating, $8 Price Target

MT Newswires Live
·
08 Nov 2024

BRIEF-SP IKT Holdings Reports 8.69% Passive Stake In Inhibikase Therapeutics Inc As Of Oct 21

Reuters
·
29 Oct 2024

SP Ikt Holdings Llc Reports 8.69% Passive Stake in Inhibikase Therapeutics Inc as of October 21 - SEC Filing

THOMSON REUTERS
·
29 Oct 2024

Sands Capital Life Sciences Pulse Fund Ii, L.p. Reports 16.3% Passive Stake in Inhibikase Therapeutics, Inc as of Oct 21 - SEC Filing

THOMSON REUTERS
·
26 Oct 2024